As the kinetics of renal glucose concentrations during an oral glucose challenge in patients undergoing SGLT2‐inhibition treatment are not entirely clear, dynamic DMI with increased spatial resolution could enhance the understanding of renal metabolism, potentially optimize treatment strategies for diabetes and CKD, and aid the development of new interventions for renal and cardiovascular health. This evidence concerns the gene SLC5A2 and chronic kidney disease.